Evidence-Based Health Solutions
Victory Over MS - Hello Friends:
I was diagnosed with Multiple Sclerosis in June 2000. Even though I had been taking Beta-Serone (one of the approved MS drugs), most doctors agreed that the medications could slow the progression of the disease but that ultimately, I would succumb to the illness, leading to permanent disability and possibly death. I have a younger sister back in Massachusetts who was diagnosed 6 years earlier, and she is almost completely incapacitated. So when I learned about the health benefits of some special nutrients and how they worked, I was very skeptical but willing to at least try them, since I had tried just about every alternative "cure" I could get my hands on. You see, I had been taking Beta-Serone for close to 2 years, and my body was still getting weaker and weaker.
In June 2002, I discovered some special nutrients through my friend Jack Kettler and have been seeing positive results in my health. Jack also had his own unique health challenges before using nutrients.
I received my first shipment of nutrients and started taking them right away, but I didn’t take them consistently! I followed the directions on the bottles, but I would take them for about 5 days, miss 2 days, take them for 3 days, miss 1 day, etc. Finally, I ran out of product and didn’t think to reorder until the 3rd day, when I realized how weak and tired I was. I reordered, followed the instructions on the bottle, and started feeling good again.
By August, I was feeling even better, but I wasn’t getting the same results as other MS folks. I was then told that the recommended amount on the bottle of the nutrient product was for healthy people to maintain optimum wellness, but that folks like me with an autoimmune disease needed to double the recommended amount every 3 days until I reached a level where I felt strong and healthy. It made sense to me, so I kept doubling the amount from 1/4 tsp until I reached 4 tsp per day. WOW! What a difference. But I was STILL SKEPTICAL. So I stopped taking it for about 2 days, and by the 3rd day I almost couldn’t get out of bed. It took me 3 days to feel good again.
To give an overview of my MS history, my neurologist, who is very well respected in northern Colorado, orders an MRI of my brain once every year. I had an MRI in August 2001 and a subsequent one in October 2001 because the August 2001 MRI showed a significant increase in lesions on my brain, many of which were active. My neurologist was so alarmed that he ordered a follow-up MRI to see whether he should re-diagnose me as Secondary Progressive MS so he could change the protocol for my treatment. The repeat MRI in October 2001 showed that the lesions were active and that their count had doubled. My condition was going downhill.
A year later, in October 2002, I had another MRI after taking nutrients for five months. When my neurologist received the results, he stared at the computer screen for a couple of minutes, then turned to me and asked what had changed in my life. When I asked why, he told me that not only were there no new lesions since my last MRI, but the ones that were still there were shrinking! I then told him about the nutrients. He told me that he had 2 other MS patients who were taking glyconutrients and were also doing very well. But he got upset when I told him I was no longer going to be using the Beta-Serone at $1200 per month. He is convinced that I will eventually need to go back to Beta Serone. Even though he saw the results with his own eyes, his training will not allow him to accept what the nutrients have done for me.
Today, after being on this level of nutrients, I have my balance, energy, and stamina back. My hands are not numb anymore. When my daughter asks me to go walking with her, I can actually walk 2 miles at a relatively brisk pace without losing balance or feeling like there are 100lb weights on my legs. Anyone who has ever been diagnosed with MS will totally understand what I’m talking about.
God bless Jack Kettler for introducing me to these nutrients. My prayer has been answered, and my life and health have been restored.
Sincerely,
Francis Connell
Medical Disclaimer
The story above reflects Francis Connell’s personal experience and is shared for informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, including Multiple Sclerosis.
Dietary supplements such as glyconutrients are not evaluated by the FDA and are not intended to replace professional medical care or prescribed medications. Individual results vary significantly. What worked for one person may not work for another.
Important: Never stop or change any prescribed medication, including disease-modifying therapies for MS, without first consulting your physician. Doing so can be dangerous. Always speak with a qualified healthcare professional before starting any new supplement, especially if you have a serious medical condition.
This testimonial does not constitute medical advice. Please consult your doctor before making any decisions regarding your health or treatment plan.
Anecdotal Evidence for the Potential Benefits of Nutritional Supplementation in Autoimmune Conditions: A Descriptive Case Series
Glyconutritional supplementation, which provides a spectrum of plant-derived monosaccharides (including mannose, fucose, galactose, and N-acetylglucosamine) intended to support the synthesis of glycoproteins and glycolipids, has garnered attention in integrative medicine for its purported role in modulating cell-to-cell communication and immune homeostasis. Although randomized controlled trials remain limited, a growing body of anecdotal reports from individuals with autoimmune disorders suggests that consistent supplementation may attenuate symptom severity and improve quality-of-life metrics. This short communication synthesizes four representative patient narratives from clinical practice and peer-reported experiences to illustrate potential adjunctive benefits across diverse autoimmune pathologies.
A 48-year-old female diagnosed with rheumatoid arthritis (RA) in 2018 achieved only partial control of symmetric polyarthritis with standard disease-modifying antirheumatic drug (DMARD) therapy. After self-initiating a glyconutritional complex (2 g daily) in early 2022, the patient documented a progressive decline in morning stiffness and tender-joint count within six weeks, which was corroborated by a 40% reduction in serum C-reactive protein (CRP) levels at the three-month follow-up. She reported sustained functional improvement, including resumption of daily yoga practice, without escalation of pharmacologic therapy.
A 35-year-old male with relapsing-remitting multiple sclerosis (RRMS), diagnosed after two demyelinating episodes and confirmed by magnetic resonance imaging, experienced persistent fatigue and gait instability despite interferon-β treatment. After starting glyconutritional supplementation at 1.5 g twice daily, he reported a marked reduction in perceived fatigue (as measured by the Fatigue Severity Scale, dropping from 5.8 to 3.2 over four months) and improved ambulation distance. Serial self-reported Expanded Disability Status Scale (EDSS) scores stabilized, prompting the patient to describe the intervention as “restorative to cellular energy and coordination.”
A 42-year-old woman with systemic lupus erythematosus (SLE), characterized by malar rash, photosensitivity, and class III lupus nephritis, experienced recurrent flares despite hydroxychloroquine and low-dose prednisone. Integration of glyconutritional support (3 g daily) coincided with the visible resolution of cutaneous lesions within 8 weeks and normalization of anti-dsDNA titers at a 6-month laboratory assessment. The patient further reported fewer hospitalizations and improved sleep quality, attributing these changes to improved immune modulation at the glycocalyx level.
Finally, a 29-year-old male with plaque psoriasis and concurrent psoriatic arthritis, refractory to topical corticosteroids and methotrexate, showed near-complete clearance of erythematous plaques and reduced joint swelling after three months of glyconutritional therapy (2 g daily). Dermatology indices (Psoriasis Area and Severity Index) fell by 75%, and the patient discontinued methotrexate under physician supervision without recurrence.
These anecdotal accounts, though subject to placebo effects, reporting bias, and confounding lifestyle factors, converge on themes of reduced inflammatory burden, improved symptom control, and better daily functioning. Mechanistically, proponents hypothesize that glyconutrients promote proper glycosylation of immune receptors, thereby dampening aberrant autoantibody production and cytokine dysregulation. Nonetheless, these observations underscore the need for rigorous, double-blind, placebo-controlled investigations to establish causality and define optimal dosing regimens. In the interim, these preliminary narratives may inform hypothesis generation and encourage clinicians to consider glyconutritional adjuncts within a personalized, multidisciplinary framework for autoimmune disease management.
Acemannan’s Immunomodulatory Mechanisms in Autoimmune Contexts
Acemannan, a highly acetylated β-(1,4)-linked polymannose polysaccharide derived from the inner leaf gel of Aloe vera, exerts context-dependent immunomodulatory effects, positioning it as a potential regulator of dysregulated immune responses in autoimmune diseases. Unlike broad immunosuppressants, acemannan modulates both innate and adaptive immunity through receptor-mediated signaling, macrophage polarization, and recalibration of the cytokine network, thereby potentially restoring tolerance to self-antigens without inducing global immune paralysis. Preclinical and patent-derived evidence highlights its capacity to alter responses to “self” antigens, as observed in models of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS).
Central to acemannan’s action is its interaction with pattern-recognition receptors on antigen-presenting cells. It binds mannose receptors, Toll-like receptor 4 (TLR4), and TLR5 on macrophages and dendritic cells (DCs), triggering downstream signaling that fine-tunes activation states. In inflammatory milieus that mimic autoimmune flares, such as lipopolysaccharide (LPS)-induced models, acemannan activates the PI3K/Akt/GSK-3β pathway, enhancing mitochondrial oxidative phosphorylation (OXPHOS) and promoting a phenotypic shift from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages. This transition increases phagocytic capacity while suppressing excessive release of TNF-α, IL-6, IL-8, CXCL10, MCP-1, and nitric oxide (NO), thereby attenuating cytokine-driven tissue damage characteristic of RA synovitis or SLE nephritis.
In adaptive immunity, acemannan exhibits dual, dose-dependent regulation of T-cell subsets. In controlled settings, it can stimulate cytotoxic T-cell proliferation and cytotoxicity, yet in autoimmune-relevant contexts, it inhibits effector T-cell expansion: studies demonstrate reduced CD25 expression on CD3⁺ T cells, decreased secretion of IL-2, IFN-γ, and IL-17A (a key Th17 cytokine implicated in RA and MS pathogenesis), and overall suppression of autoreactive lymphocyte activity. This selective dampening of pathogenic effector responses, coupled with preserved or enhanced regulatory networks, aligns with patent claims for acemannan’s utility in modulating self-antigen reactivity and reducing plaque formation in MS models.
Dendritic cell modulation further supports tolerance induction. Acemannan upregulates MHC-II and co-stimulatory molecules (B7-1, B7-2, CD40, CD54) on immature DCs in some paradigms, yet in inflammatory environments, its net effect favors resolution rather than amplification of autoreactivity. By enhancing antigen clearance through improved phagocytosis while limiting excessive co-stimulation, acemannan may recalibrate DC–T-cell interactions, thereby reducing the perpetuation of autoantibody production and immune complex deposition seen in SLE.
These mechanisms converge on balanced immunomodulation that addresses core autoimmune dysregulations: unchecked M1-driven inflammation, Th17/Th1 skewing, and impaired self-tolerance. In RA models, acemannan’s anti-arthritic profile stems from its ability to suppress synovial cytokine storms and promote tissue repair. In broader autoimmune contexts, it is proposed to resolve lesions in inflammatory bowel disease and MS by reducing local autoimmune immunoglobulin deposition and fostering regenerative microenvironments.
Although rigorous randomized trials in human autoimmune cohorts remain limited, documented receptor engagement, PI3K/Akt/GSK-3β-mediated macrophage reprogramming, and selective T-cell suppression provide a mechanistic rationale for acemannan’s adjunctive role. Its actions appear particularly suited to conditions marked by chronic low-grade inflammation and cytokine imbalance, offering a plant-derived strategy to recalibrate rather than abolish immune homeostasis. Further elucidation of dose- and disease-stage-specific effects will be essential to translate these pathways into targeted autoimmune therapies.
Your body constantly renews itself by producing new cells to replace old or damaged ones, but this process depends on a daily supply of essential nutrients from food and supplements. These building blocks create strong, functional cells, support a robust immune system, and activate your body’s innate healing ability. To learn more about the science behind the most important glyconutrient, acemannan, just ask the person who gave this to you.
Click on the email link to send us a request explaining your need for help to get more details on the products I use, how to order them, and why all 500 thousand people in the US who suffer from MS can benefit from these nutrients.
I have my life back without the toxic MS drugs and want you to have the same kind of Victory Over MS that I have experienced.
God Bless,
Francis Connell
Contact us:
Use our secure, encrypted email based in Switzerland to provide the following information so we can better serve you.
Provide the following:
First and last name
Phone number
Message us with your questions
Send to VOVERMS@proton.me. Simply copy and paste VOVERMS@proton.me into the send-to line in your email program. To retrieve our auto-reply, be sure to check your spam folder!
We will never sell or trade your information to anyone!